Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1864 results
April 2015
-
Press Release
Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mg
Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Novartis and Sandoz are driving access to a full… -
Press Release
Alcon receives FDA approval of new multifocal intraocular lens to treat cataract patients in the United States
US Food and Drug Administration (FDA) grants approval of the AcrySof® IQ ReSTOR® +2.5 Diopter (D) Intraocular Lens (IOL) for sale in the US Expands Alcon's IOL portfolio for the … -
Press Release
Data in The Lancet show Novartis drug Arzerra® plus chlorambucil improved median progression-free survival by 71% in CLL patients
Significant improvement in PFS seen with Arzerra plus chlorambucil in previously untreated patients with CLL for whom fludarabine-based therapy was inappropriate Chronic lymphocytic… -
Story From Our Labs
Cancer spies find drug-beating covert cells
-
Press Release
Gilenya® data at AAN to highlight Novartis leadership in innovation with new MS assessment methods to benefit patients and physicians
New analysis will confirm high efficacy of Gilenya® in achieving 'no evidence of disease activity' (NEDA4) in previously-treated highly-active RMS patients Separate analyses will show adding…
March 2015
-
Press Release
Novartis announces FDA approval for JadenuTM to simplify treatment administration for patients with chronic iron overload
Jadenu (deferasirox), a new formulation of Exjade (deferasirox), is the only once-daily oral tablet for iron chelation Jadenu, taken with or without food, simplifies daily treatment… -
Story Discovery
New recruit has big dreams for cancer immunotherapy
Immunotherapy for cancer is on the brink of breakthroughs. Learn how NIBR have high expectations for this medical science.
-
Press Release
Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group
Collaboration with Aduro is focused on discovery and development of next generation cancer immunotherapies targeting the STING signaling pathway Addition of STING agonists further enhances… -
Press Release
Novartis' Cosentyx(TM) two-year data shows sustained effect and favorable safety profile in psoriasis patients
After two full years of therapy with Cosentyx 300 mg, almost 9 out of 10 psoriasis patients sustained their PASI 75 response[1] New data at AAD shows 7 out of 10 psoriasis patients, who… -
Press Release
New Novartis data shows Cosentyx(TM) is significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of psoriasis patients
CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx(TM) compared to Stelara® at Week 16[1] Cosentyx showed greater improvements… -
Story Patient Perspectives
Psoriasis: The story of a hidden condition
More than 125 million people worldwide live with psoriasis, a chronic autoimmune disease that causes red, scaly patches to appear on the skin.
-
Press Release
Novartis receives EU approval for Jakavi® in polycythemia vera, first targeted therapy approved for patients with this rare blood cancer
Jakavi® (ruxolitinib) approved by the European Commission for adult patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea PV is a rare blood cancer associated with…